0001209191-23-024879.txt : 20230419 0001209191-23-024879.hdr.sgml : 20230419 20230419174003 ACCESSION NUMBER: 0001209191-23-024879 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230417 FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TRENARY C RUSSELL III CENTRAL INDEX KEY: 0001227307 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 23830896 MAIL ADDRESS: STREET 1: 1700 E ST ANDREW PLACE CITY: SANTA ANA STATE: CA ZIP: 92705 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-17 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001227307 TRENARY C RUSSELL III 485 ROUTE 1 SOUTH, BUILDING F SUITE 320 ISELIN NJ 08830 1 1 0 0 CEO and President 0 Stock Option (Right to Buy) 1.08 2023-04-17 4 A 0 257143 0.00 A 2033-04-17 Common Stock 257143 257143 D 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. /s/ Lawrence Kenyon, Attorney-in-Fact 2023-04-19